Role of dietary supplements in lowering low-density lipoprotein cholesterol: A review

Journal of Clinical Lipidology

Volumn 4, Issue 4, 2010, Pages 248-258

  Nijjar, Prabhjot S ^a   Burke, Frances M ^a   Bloesch, Annette ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Dietary supplement; LDL cholesterol; Nutraceutical; Supplement

Indexed keywords

CHOLESTIN; CYTELLIN; DAIDZIN; GENISTIN; GUGGULSTERONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PHYTOSTEROL; POLICOSANOL; SIMVASTATIN; SOYBEAN PROTEIN; STANOZOLOL; HYPOCHOLESTEROLEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GARLIC; HUMAN; NUT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; METABOLISM;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIETARY FIBER; DIETARY SUPPLEMENTS; HUMANS; PHYTOSTEROLS; SOYBEAN PROTEINS;

EID: 79953790630     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.07.001     Document Type: Review

References (148)

1. McNamara DJ. Cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529:310-320.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Food and Drug Administration. Overview of Dietary Supplements. Available at: Http://www.fda.gov/Food/DietarySupplements/Consumer Information/ucm110417. htm#what. Accessed July 7, 2010.
5. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281-286.
6. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep. 2008;1-23.
7. Liu S, Stampfer MJ, Hu FB, et al. Whole-grain consumption and risk of coronary heart disease: Results from the Nurses' Health Study. Am J Clin Nutr. 1999;70:412-419.
8. Bazzano LA, He J, Ogden LG, Loria CM, Whelton PK. Dietary fiber intake and reduced risk of coronary heart disease inUS men andwomen: The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 2003;163:1897-1904.
9. Pereira MA, O'Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease: A pooled analysis of cohort studies. Arch Intern Med. 2004;164:370-376.
10. Anderson JW, Tietyen-Clark J. Dietary fiber: Hyperlipidemia, hypertension, and coronary heart disease. Am J Gastroenterol. 1986;81: 907-919.
11. Jenkins DJ, Josse AR, Wong JM, et al. Nutriceuticals and functional foods for cholesterol reduction. In: Ballantyne CM, editor. Clinical lipidology: A companion to Braunwald's heart disease. Philadelphia, PA: Saunders Elsevier, 2009.
12. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: A meta-analysis. Am J Clin Nutr. 1999;69:30-42.
13. Leinonen KS, Poutanen KS, Mykkanen HM. Rye bread decreases serum total and LDL cholesterol in men with moderately elevated serum cholesterol. J Nutr. 2000;130:164-170.
14. Blundell JE, Burley VJ. Satiation, satiety and the action of fibre on food intake. Int J Obes. 1987;11:9-25.
15. Kris-Etherton PM, Krummel D, Russell ME, et al. The effect of diet on plasma lipids, lipoproteins, and coronary heart disease. J Am Diet Assoc. 1988;88:1373-1400.
16. Ripsin CM, Keenan JM, Jacobs DR Jr., et al. Oat products and lipid lowering. A meta-analysis. JAMA. 1992;267:3317-3325.
17. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr. 1995;61:585-589.
18. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: Meta-analysis of 8 controlled trials. Am J Clin Nutr. 2000;71:472-479.
19. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161-1166.
20. Fernandez ML, Vega-Lopez S. Efficacy and safety of sitosterol in the management of blood cholesterol levels. Cardiovasc Drug Rev. 2005; 23:57-70.
21. Pollak OJ, Kritchevsky D, editors. Sitosterol Monographs Atherosclerosis. Vol. 10. Basel: Karger, 1981.
22. European Commission. General view of the scientific committee on food on the long term effects of the intake of elevated levels of phytosterols from multiple dietary sources. Scientific committee on food. Brussels, Belgium; 2002. Available at: Http://ec.europa.eu/food/fs/sc/scf/out143-en.pdf. Accessed July 7, 2010.
23. Ito T, Tamura T, Matsumoto T. Sterol composition of 19 vegetable oils. J Am Oil Chem Soc. 1973;50:122-125.
24. Amaral JS, Casal S, Pereira JA, Seabra RM, Oliveira BP. Determination of sterol and fatty acid compositions, oxidative stability, and nutritional value of six walnut (Juglans regia L.) cultivars grown in Portugal. J Agric Food Chem. 2003;51:7698-7702.
25. Patch CS, Tapsell LC, Williams PG, Gordon M. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: Theory and evidence. Vasc Health Risk Manag. 2006;2:157-162.
26. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res. 2000;41: 697-705.
27. Berger A, Jones PJ, Abumweis SS. Plant sterols: Factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis. 2004;3:5.
28. Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanol esterenriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr. 2000;54:715-725.
29. Weingartner O, Bohm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30:404-409.
30. Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of cardiovascular diseases. Ann Med. 2004;36:126-134.
31. Fransen HP, de Jong N, Wolfs M, et al. Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterol and stanol concentrations in humans. J Nutr. 2007;137:1301-1306.
32. Talati R, Sobieraj DM, Makanji SS, Phung OJ, Coleman CI. The comparative efficacy of plant sterols and stanols on serum lipids: A systematic review and meta-analysis. J Am Diet Assoc;110:719-726.
33. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-1312.
34. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000;130:767-776.
35. Volpe R, Niittynen L, Korpela R, et al. Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia. Br J Nutr. 2001;86:233-239.
36. Davidson MH, Maki KC, Umporowicz DM, et al. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr. 2001;20:307-319.
37. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr. 2002;76:1272-1278.
38. Devaraj S, Jialal I, Vega-Lopez S. Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24: E25-e28.
39. Goldberg AC, Ostlund RE Jr., Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA. Effect of plant stanol tablets on lowdensity lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006;97:376-379.
40. Demonty I, Ras RT, van der Knaap HC, et al. Continuous doseresponse relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr. 2009;139:271-284.
41. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: Relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol. 2000;20:1340-1346.
42. Vanhanen H. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients. Eur J Clin Pharmacol. 1994;47:169-176.
43. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: Women and dietary sitostanol. Circulation. 1997;96: 4226-4231.
44. Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis. 2001;156:329-337.
45. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol. 2002;90:737-740.
46. Clifton PM, Noakes M, Sullivan D, et al. Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J Clin Nutr. 2004;58:503-509.
47. Van Horn L, McCoin M, Kris-Etherton PM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc. 2008;108:287-331.
48. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest. 1974;53:1033-1043.
49. Lu K, Lee MH, Hazard S, et al. Two genes that map to the STSL locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001;69:278-290.
50. Salen G, Shefer S, Nguyen L, Ness GC, Tint GS, Shore V. Sitosterolemia. J Lipid Res. 1992;33:945-955.
51. Kwiterovich PO Jr., Chen SC, Virgil DG, Schweitzer A, Arnold DR, Kratz LE. Response of obligate heterozygotes for phytosterolemia to a low-fat diet and to a plant sterol ester dietary challenge. J Lipid Res. 2003;44:1143-1155.
52. Wilund KR, Yu L, Xu F, et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol. 2004;24:2326-2332.
53. Miettinen TA, Railo M, Lepantalo M, Gylling H. Plant sterols in serum and in atherosclerotic plaques of patients undergoing carotid endarterectomy. J Am Coll Cardiol. 2005;45:1794-1801.
54. Clifton PM, Noakes M, Ross D, Fassoulakis A, Cehun M, Nestel P. High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering. J Lipid Res. 2004;45:1493-1499.
55. Noakes M, Clifton P, Ntanios F, Shrapnel W, Record I, McInerney J. An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr. 2002;75:79-86.
56. Hilleboe HE. Some epidemiologic aspects of coronary artery disease. J Chronic Dis. 1957;6:210-228.
57. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: An American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034-1044.
58. Ignatowski AI. Ueber die Wirkung der tiershen Einwesses auf der Aorta. Virchow's Arch Pathol Anat. 1909;198:248.
59. Sirtori CR, Agradi E, Conti F, Mantero O, Gatti E. Soybean-protein diet in the treatment of type-II hyperlipoproteinaemia. Lancet. 1977; 1:275-277.
60. Carroll KK. Hypercholesterolemia and atherosclerosis: Effects of dietary protein. Fed Proc. 1982;41:2792-2796.
61. Carroll KK. Review of clinical studies on cholesterol-lowering response to soy protein. J Am Diet Assoc. 1991;91:820-827.
62. Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: Importance of the chemical composition of soyabean products. Br J Nutr. 1995;74:587-601.
63. Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 1999;159: 2070-2076.
64. Lovati MR, Manzoni C, Gianazza E, et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr. 2000; 130:2543-2549.
65. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: A meta-analysis. Eur J Clin Nutr. 2003;57:940-946.
66. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
67. Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis. 2008;200:13-27.
68. Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol. 2006;98:633-640.
69. Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA. 2005;294: 2455-2464.
70. Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. Arch Intern Med. 2002;162:1382-1387.
71. Ellsworth JL, Kushi LH, Folsom AR. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: The Iowa Women's Health Study. Nutr Metab Cardiovasc Dis. 2001;11:372-377.
72. Fraser GE, Sabate J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med. 1992;152:1416-1424.
73. Hu FB, Stampfer MJ, Manson JE, et al. Frequent nut consumption and risk of coronary heart disease in women: Prospective cohort study. BMJ. 1998;317:1341-1345.
74. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 1992;12:911-919.
75. Li L, Tsao R, Yang R, Kramer JK, Hernandez M. Fatty acid profiles, tocopherol contents, and antioxidant activities of heartnut (Juglans ailanthifolia Var. cordiformis) and Persian walnut (Juglans regia L.). J Agric Food Chem. 2007;55:1164-1169.
76. Sabate J, Fraser GE, Burke K, Knutsen SF, Bennett H, Lindsted KD. Effects of walnuts on serum lipid levels and blood pressure in normal men. N Engl J Med. 1993;328:603-607.
77. Spiller GA, Jenkins DA, Bosello O, Gates JE, Cragen LN, Bruce B. Nuts and plasma lipids: An almond-based diet lowers LDL-C while preserving HDL-C. J Am Coll Nutr. 1998;17:285-290.
78. Chisholm A, Mann J, Skeaff M, et al. A diet rich in walnuts favourably influences plasma fatty acid profile in moderately hyperlipidaemic subjects. Eur J Clin Nutr. 1998;52:12-16.
79. Edwards K, Kwaw I, Matud J, Kurtz I. Effect of pistachio nuts on serum lipid levels in patients with moderate hypercholesterolemia. J Am Coll Nutr. 1999;18:229-232.
80. Morgan WA, Clayshulte BJ. Pecans lower low-density lipoprotein cholesterol in people with normal lipid levels. J Am Diet Assoc. 2000;100:312-318.
81. Curb JD, Wergowske G, Dobbs JC, Abbott RD, Huang B. Serum lipid effects of a high-monounsaturated fat diet based on macadamia nuts. Arch Intern Med. 2000;160:1154-1158.
82. Zambon D, Sabate J, Munoz S, et al. Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women. A randomized crossover trial. Ann Intern Med. 2000;132:538-546.
83. Rajaram S, Burke K, Connell B, Myint T, Sabate J.Amonounsaturated fatty acid-rich pecan-enriched diet favorably alters the serum lipid profile of healthy men and women. J Nutr. 2001;131:2275-2279.
84. Jenkins DJ, KendallCW,Marchie A, et al. Dose response of almonds on coronary heart disease risk factors: Blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: A randomized, controlled, crossover trial. Circulation. 2002;106: 1327-1332.
85. Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE. Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr. 2001;74:72-79.
86. Kris-Etherton PM, Pearson TA, Wan Y, et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr. 1999;70:1009-1015.
87. Banel DK, Hu FB. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: A meta-analysis and systematic review. Am J Clin Nutr. 2009;90:56-63.
88. Sabate J, Cordero-Macintyre Z, Siapco G, Torabian S, Haddad E. Does regular walnut consumption lead to weight gain? Br J Nutr. 2005;94:859-864.
89. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a lowcarbohydrate diet for obesity. N Engl JMed. 2003;348(21):2082-2090.
90. Kris-Etherton PM, Zhao G, Binkoski AE, Coval SM, Etherton TD. The effects of nuts on coronary heart disease risk. Nutr Rev. 2001; 59:103-111.
91. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231-236.
92. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial. Ann Intern Med. 2009;150:830-839, W147-W149.
93. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 1979;32:852-854.
94. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005; 153:679-686.
95. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. Efficacy of Monascus purpureusWent rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14:438-440.
96. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
97. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proc. 2008;83:758-764.
98. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
99. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol;105:198-204.
100. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-1693.
101. Moore R. Letter to Sonia Rodriguez, Mason Vitamins. May 5 2001.
102. US department of health and human services website. Available at: Http://www.fda.gov/ohrms/dockets/dailys/01/Jun01/061101/let0494.pdf. Accessed July 7, 2010.
103. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: Implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7:133-139.
104. Cartin-Ceba R, Lu LB, Kolpakchi A. A 'natural' threat. Am J Med. 2007;120:e3-e4.
105. Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: Spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66:572-574.
106. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145:474-475.
107. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200-1201.
108. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med. 2008;149:516-517.
109. Lin YL, Wang TH, Lee MH, Su NW. Biologically active components and nutraceuticals in the Monascus-fermented rice: A review. Appl Microbiol Biotechnol. 2008;77:965-973.
110. ConsumerLab.com Product Review: Red Yeast Rice Supplements. Available at: Http://www.consumerlab.com/reviews/Red-Yeast-Rice-Supplements-Lovastatin- Monacolin/Red-Yeast-Rice/. Accessed July 7, 2010.
111. Janikula M. Policosanol: A new treatment for cardiovascular disease? Altern Med Rev. 2002;7:203-217.
112. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr. 2006;95:968-975.
113. Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
114. Torres O, Agramonte AJ, Illnait J, Mas Ferreiro R, Fernandez L, Fernandez JC. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
115. Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol. 2000;14:187-195.
116. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res. 1999;19: 117-127.
117. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging. 2003;20:153-163.
118. Castano G, Mas Ferreiro R, Fernandez L, Gamez R, Illnait J, Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology. 2001;52:115-125.
119. Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14- month pilot study. Int J Clin Pharmacol Ther. 1996;34:134-137.
120. Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism. 2004;53: 1309-1314.
121. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: A randomized controlled trial. JAMA. 2006;295:2262-2269.
122. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: A randomized controlled trial. Am J Clin Nutr. 2006;84:1543-1548.
123. Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr. 2001;131:1000S-1005S.
124. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: Human and animal studies. J Nutr. 2001;131: 989S-993S.
125. Borek C. Garlic reduces dementia and heart-disease risk. J Nutr. 2006;136:810S-812S.
126. Reuter HD, Koch H, Lawson LD. Therapeutic effects and applications of garlic and its preparations. In: Koch H, Lawson LD, editors. GarlicdThe Science and Therapeutic application of Allium Sativum Land-Related Species. Baltimore: Williams & Wilkins, 1996.
127. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med. 1993;119:599-605.
128. Silagy C, Neil A. Garlic as a lipid lowering agentda meta-analysis. J R Coll Physicians Lond. 1994;28:39-45.
129. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420-429.
130. Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: A randomized clinical trial. Arch Intern Med. 2007;167:346-353.
131. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: A randomized controlled trial. JAMA. 1998;279:1900-1902.
132. Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. Atherosclerosis. 2001;154:213-220.
133. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: A multicenter, randomized, placebo-controlled trial. Arch Intern Med. 1998;158:1189-1194.
134. Superko HR, Krauss RM. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, highdensity lipoprotein subclass distribution and lipoprotein(a). J Am Coll Cardiol. 2000;35:321-326.
135. Ernst E. Cardiovascular effects of garlic (Allium sativum): A review. Pharmatherapeutica. 1987;5:83-89.
136. Satyavati GV. Gum guggul (Commiphora mukul)dthe success story of an ancient insight leading to a modern discovery. Indian J Med Res. 1988;87:327-335.
137. Nityanand S, Kapoor NK. Cholesterol lowering activity of the various fractions of the guggal. Indian J Exp Biol. 1973;11:395-396.
138. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002; 296:1703-1706.
139. Gopal K, Saran RK, Nityanand S, et al. Clinical trial of ethyl acetate extract of gum gugulu (gugulipid) in primary hyperlipidemia. J Assoc Physicians India. 1986;34:249-251.
140. Agarwal RC, Singh SP, Saran RK, et al. Clinical trial of gugulipidda new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626-634.
141. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA. 2003;290:765-772.
142. Us-Fda. United States Food and Drug Administration. FDA final rule for food labelling: Health claims: Soy protein and coronary heart disease (federal register 64 57699-57733). 1999. Available at: Http://www. fda.gov/Food/ LabelingNutrition/LabelClaims/HealthClaimsMeeting SignificantScientificAgreementSSA/ucm074740.htm. Accessed July 7, 2010.
143. Us-Fda. United states Food and Drug Administration. FDA final rule for food labelling:Health claims: Nuts and heart disease (federal register docket no. 02P-0505). 2003. Available at: Http://www.fda.gov/Food/ LabelingNutrition/ LabelClaims/QualifiedHealthClaims/ucm073992. htm#nuts. Accessed July 7, 2010.
144. Gardner CD, Coulston A, Chatterjee L, Rigby A, Spiller G, Farquhar JW. The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults: A randomized trial. Ann Intern Med. 2005; 142:725-733.
145. Lukaczer D, Liska DJ, Lerman RH, et al. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition. 2006;22:104-113.
146. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502-510.
147. Jenkins DJ, Kendall CW, Faulkner DA, et al. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr. 2006;83:582-591.
148. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135:262-268.